[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adjuvant-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adjuvant-therapy":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,47,74,98,124,147,177,199,222,250,274,294,316,342,369,392,412,439,463,484],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100616259","phase-2-becotatug-vedotin-as-adjuvant-therapy-for-high-risk-nasopharyngeal-carcinoma-100616259",false,"NCT07303283","Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma","Single-agent Becotatug Vedotin as Adjuvant Therapy for High-risk Locoregional Advanced Nasopharyngeal Carcinoma: a Multicentre, Open-label, Parallel-group, Randomised, Controlled, Phase 2 Trial","Inclusion Criteria:\n\n1. Histologically confirmed non-keratinizing nasopharyngeal carcinoma(WHO II\u002FIII).\n2. Eligible patients with high-risk locoregionally advanced NPC, defined as AJCC (9th edition) stage T4N1M0 or Tany N2-3M0 disease, or persistent high-risk features after induction chemotherapy (SD, PD, or detectable plasma EBV DNA).\n3. ECOG performance status ≤1.\n4. Induction and concurrent chemoradiotherapy with the recommended regimen have been completed.\n5. No later than 6 weeks after the completion of the last radiotherapy treatment.\n6. Adequate hematologic (neutrophil count \\> 1.5×10\\^9\u002FL, hemoglobin \\> 90g\u002FL and platelet count \\> 100×10\\^9\u002FL), hepatic (alanine aminotransferase, aspartate aminotransferase ≤ 1.5×ULN, bilirubin ≤ 1.5×ULN, alkaline phosphatase \\\u003C 2.5×ULN) and renal function (creatinine clearance \\> 50 ml\u002Fmin)\n7. Patients must be informed of the investigational nature of this study and give written informed consent.\n8. Women of childbearing potential (WOCBP) who are sexually active must be willing to adhere to effective contraception during treatment and for 1 year after the last dose of the study drug. Men who are sexually active with WOCBP must be willing to adhere to effective contraception during treatment and for 1 year after the last dose of the study drug.\n\nExclusion Criteria:\n\n1. Patients who could not tolerate or were allergic to Becotatug Vedotin.\n2. Patients with severe chronic or active infection that must be treated with systemic antibacterial, antifungal, or antiviral therapy before randomization, including but not limited to tuberculosis infection.\n3. Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer.\n4. Pregnancy or lactation (consider pregnancy test in women of child-bearing age and emphasize effective contraception during the treatment period).\n5. Interstitial lung disease or pneumonia requiring oral or intravenous steroid therapy within 1 year.\n6. Patients who are known to be intolerant or sensitive to any therapeutic agents.\n7. Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose \\> 1.5×ULN), and emotional disturbance.","ALL","18 Years","65 Years",{"count":20,"type":21},140,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a phase 2, multicentre, open-label, randomised, controlled trial with a parallel-group design. The study aims to evaluate the efficacy and safety of single-agent Becotatug Vedotin as adjuvant therapy in patients with high-risk locoregionally advanced nasopharyngeal carcinoma (NPC).",[27,28,29],"Nasopharyngeal Carcinoma (NPC)","Locoregionally Advanced Nasopharyngeal Carcinoma","Adjuvant Therapy",[31,32,33],"Nasopharyngeal Carcinoma","Adjuvant therapy","Becotatug Vedotin","NOT_YET_RECRUITING","2026-06-06",{"date":37,"type":38},"2026-06-09","ACTUAL",{"date":40,"type":21},"2026-09-01",{"date":42,"type":21},"2033-08-31",{"name":44,"class":45},"Kai Hu","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":46},"100638471","a-prospective-multicenter-phase-ii-clinical-study-of-postoperative-chemotherapy-combined-with-ql1706-for-high-risk-triple-negative-breast-cancer-100638471","NCT07622836","A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer.","Inclusion Criteria:\n\n1. The participant voluntarily joins this study and signs the informed consent form.\n2. Female breast cancer participants aged ≥18 and ≤75 years, with a histologically or cytologically confirmed diagnosis of TNBC (IHC 0, IHC 1+, or IHC 2+\u002FISH-) based on the most recent biopsy or other pathological specimen, according to the latest ASCO\u002FCAP guidelines. Patients with low ER or PR expression (1%-10%) may also be included in this study.\n3. Patients with high-risk TNBC (defined as lymph node-positive).\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n5. Agree to provide intraoperatively obtained tumor histopathological specimens (FFPE, at least 5 sections) for biomarker testing.\n6. Expected survival ≥3 months.\n7. Function of vital organs meets the following requirements (use of any blood components or cell growth factors within 14 days before the first dose is not allowed):\n\n   * Absolute neutrophil count ≥1.5×10⁹\u002FL;\n   * Platelet count ≥100×10⁹\u002FL;\n   * Hemoglobin ≥90 g\u002FL;\n   * Serum albumin ≥30 g\u002FL;\n   * Thyroid-stimulating hormone (TSH) ≤1×ULN (if abnormal, FT3 and FT4 levels should also be assessed; if FT3 and FT4 are within normal range, the patient may be enrolled);\n   * Serum total bilirubin ≤1.5×ULN;\n   * ALT and AST ≤2.5×ULN; in the presence of liver metastases, ALT and AST ≤5×ULN;\n   * ALP ≤2.5×ULN (in patients with liver or bone metastases, ALP ≤5×ULN);\n   * Serum creatinine ≤1.5×ULN;\n   * International normalized ratio (INR) ≤1.5×ULN (not receiving anticoagulation therapy).\n8. Female participants who are not surgically sterilized or are of childbearing potential must use a medically approved contraceptive method (such as an intrauterine device, contraceptive pill, or condom) during the study treatment period and for 3 months after the end of the study treatment. Female participants of childbearing potential who are not surgically sterilized must have a negative serum or urine HCG test within 7 days before the first dose and must not be lactating.\n\nExclusion Criteria:\n\n1. Presence of any active autoimmune disease or history of autoimmune disease (e.g., including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism); however, participants with the following conditions are allowed to enroll: vitiligo, psoriasis, alopecia not requiring systemic treatment; well-controlled type I diabetes mellitus; hypothyroidism stable on hormone replacement; childhood asthma that has completely resolved and requires no intervention in adulthood; asthma requiring bronchodilators for medical intervention is excluded.\n2. Current use of immunosuppressants or systemic corticosteroid therapy for immunosuppressive purposes (dose \\>10 mg\u002Fday prednisone or equivalent) within 2 weeks prior to enrollment.\n3. History of severe hypersensitivity reaction to other monoclonal antibodies.\n4. Prior discontinuation of anti-PD-1\u002FPD-L1 antibody therapy due to related toxicity.\n5. Known history or evidence of interstitial lung disease or active non-infectious pneumonitis.\n6. History of CNS metastases or current central nervous system (CNS) metastases. Baseline imaging to rule out brain metastases is not mandatory. Patients with unknown CNS metastasis status but with any clinical signs suggestive of CNS metastases are eligible only if CT and\u002For MRI scans rule out CNS metastases.\n7. Previous history of other malignancies (except for patients with non-melanoma skin cancer or carcinoma in situ of the cervix, who are eligible; patients with other prior malignancies must have been disease-free for at least 3 years).\n8. Hypertension poorly controlled with antihypertensive medication (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg); achieving the above parameters with antihypertensive treatment is allowed. History of hypertensive crisis or hypertensive encephalopathy.\n9. Within 6 months before first dose, known history of unstable angina, myocardial infarction (MI), or chronic heart failure (CHF), or known history of clinically significant arrhythmia requiring antiarrhythmic therapy (except stable atrial fibrillation), or left ventricular ejection fraction \\\u003C50%.\n10. Current thrombolytic or anticoagulant therapy; prophylactic use of low-dose aspirin or low-molecular-weight heparin is permitted.\n11. Presence of pleural effusion, ascites, or pericardial effusion requiring drainage; patients may be enrolled if clinically stable after drainage as assessed by the investigator.\n12. Arterial\u002Fvenous thrombotic events occurring within 6 months before enrollment, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism.\n13. Major vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months before start of study treatment.\n14. Major surgery (excluding diagnostic procedures) within 4 weeks before start of study treatment, or anticipated need for major surgery during the study.\n15. Urinalysis showing urine protein ≥++ and confirmed 24-hour urine protein \\>1.0 g.\n16. Prior radiotherapy (except palliative radiotherapy for bone lesions), chemotherapy, or surgery (except biopsy) with completion (last dose) less than 4 weeks before the first study dose; last dose of antibody therapy less than 4 weeks before first study dose; molecular targeted therapy (including oral targeted drugs from other clinical trials) less than 5 half-lives before first study dose, or adverse reactions from prior treatment (excluding alopecia) not recovered to ≤CTCAE grade 1.\n17. Active infection, unexplained fever ≥38.5°C within 7 days before dosing, or baseline white blood cell count \\>15×10⁹\u002FL.\n18. Congenital or acquired immunodeficiency (e.g., HIV infection); hepatitis B surface antigen (HBsAg) positive with HBV DNA ≥2000 IU\u002FmL; or hepatitis C virus antibody positive.\n19. Prior treatment with immune checkpoint inhibitors such as anti-PD-1, PD-L1, or anti-CTLA-4.\n20. Receipt of live vaccine within 4 weeks before first study dose or possible vaccination during the study period.\n21. As judged by the investigator, any other condition that may affect the study results or cause forced premature termination of the study, such as alcoholism, drug abuse, other serious diseases (including psychiatric illness) requiring concomitant treatment, severe laboratory abnormalities, or family\u002Fsocial factors that may affect patient safety.\n22. Women who are pregnant or breastfeeding.","75 Years",{"count":55,"type":21},59,[57],"NA","This study is a prospective, multicenter, phase II clinical trial designed to evaluate the efficacy and safety of postoperative chemotherapy combined with QL1706 in patients with high-risk triple-negative breast cancer.\n\nAfter enrollment, participants will receive 8 cycles of chemotherapy combined with QL1706. The standard chemotherapy regimen is the AC-T regimen (4 cycles of epirubicin plus cyclophosphamide, followed by 4 cycles of a taxane) - a Category I recommendation in the 2025 CSCO guidelines. The final choice of chemotherapy regimen is at the investigator's discretion. Starting from cycle 9, participants will receive QL1706 monotherapy as maintenance treatment. Dosing will continue until protocol-defined treatment discontinuation criteria are met, the participant experiences intolerable toxicity, or the participant withdraws informed consent. The maximum number of QL1706 dosing cycles is 17.\n\nAfter completing treatment, participants will continue to undergo post-treatment safety follow-up and survival follow-up. For participants who discontinue treatment for reasons other than disease progression or death, tumor progression follow-up will also be conducted after treatment ends.\n\nAfter enrollment, safety assessments will be performed every 3 weeks, and imaging evaluations will be performed every 12 weeks (±7 days) until confirmed disease progression per RECIST v1.1, initiation of another new anti-cancer therapy, withdrawal of informed consent, or death, whichever occurs first.",[60,29,61],"TNBC","Lymph Node Positive",[60,63],"QL1706","RECRUITING","2026-06-02",{"date":67,"type":38},"2026-06-03",{"date":69,"type":21},"2026-06-05",{"date":71,"type":21},"2030-12-31",{"name":73,"class":45},"The First Affiliated Hospital with Nanjing Medical University",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100606833","breast-cancer-relapsed-in-patients-treated-with-adjuvant-cdk46-inhibitors-100606833","NCT07180693","Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4\u002F6 Inhibitors:","Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4\u002F6 Inhibitors: Evaluation in the Real-world Setting","BREAKER","Inclusion Criteria:\n\n* Female (regardless of menopausal status) or male ≥18 years of age;\n* The patient has confirmed HR+, HER2-, early-stage resected invasive breast cancer candidate to adjuvant CDK4\u002F6 inhibitors (abemaciclib or ribociclib);\n* ER and PgR positivity is defined as evidence of immunohistochemical staining ≥ 1% according to ASCO\u002FCAP recommendations; HER2 negativity is defined as expression of the membrane protein in immunohistochemistry 0 or 1+ or with a 2+ in situ hybridization (ISH) test negative as per ASCO\u002FCAP recommendations;\n* Patients who are initiating or have initiated adjuvant treatment with a CDK4\u002F6 inhibitor (abemaciclib or ribociclib) in combination with endocrine therapy (ET). Treatment must have started on or after January 1, 2021.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;\n* Consent to data treatment according to the local regulation.\n\nExclusion Criteria:\n\n* Current participation in any other HR+\u002FHER2- EBC study with any investigational products;\n* Patients who have already received adjuvant treatment with a CDK4\u002F6 inhibitor as part of a clinical trial;\n* Patients unable to comply with the requirements of the study or who, in the judge of the study physician, should not be included in the study;\n* Patients with a history of previous BC, with the exception of Ductal carcinoma in situ (DCIS) treated by locoregional therapy alone ≥5 years ago;\n* Patients with a history of any other cancer (except non-melanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission with no therapy for a minimum of 5 years from the index date, will be excluded, as well.",{"count":83,"type":21},750,"OBSERVATIONAL","This is a multicenter observational study with both retrospective and prospective phase, designed to evaluate the clinico-pathologic characteristics and outcomes of patients with HR+\u002FHER2- EBC at high risk of recurrence treated with ribociclib or abemaciclib in combination with ET in the adjuvant setting.",[29,87],"CDK4\u002F6 Inhibitor","2026-05-28",{"date":90,"type":38},"2026-05-29",{"date":92,"type":38},"2025-09-29",{"date":94,"type":21},"2030-08-01",{"name":96,"class":45},"European Institute of Oncology",18,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":46},"100629822","phase-1-an-antibody-armored-dendritic-cell-in-patients-with-solid-tumors-100629822","NCT07479667","An Antibody-armored Dendritic Cell in Patients With Solid Tumors","An Exploratory, Single-arm, Open-label Study to Evaluate the Safety and Tolerability of Antibody-armored Dendritic Cell Injection Following a Single Administration in Patients With Solid Tumors","dendritic cell","Inclusion Criteria:\n\n* Aged 18 to 80 years, body weight ≥ 40 kg; male or female, no gender restriction;\n* ECOG performance status score of 0 to 1;\n* Histopathologically confirmed solid tumors including pancreatic cancer, colorectal cancer (CRC), gastric cancer and other such malignancies;\n* Having undergone R0 or R1 resection with completion of at least 4 cycles of standard postoperative adjuvant chemotherapy;\n* Positive expression for at least one of TERT, P53, KRAS and Survivin;\n* Sufficient venous access with no contraindications to peripheral blood mononuclear cell collection;\n* Adequate organ and bone marrow function:\n* a) Platelet count ≥ 90×10⁹\u002FL;\n* b) Hemoglobin ≥ 90 g\u002FL (no blood transfusion or erythropoietin dependence within 7 days);\n* c) Mononuclear cell count ≥ 1.0×10⁹\u002FL;\n* d) International Normalized Ratio (INR) or Prothrombin Time (PT) ≤ 1.5 × upper limit of normal (ULN);\n* e) Serum creatinine ≤ 1.5 × upper limit of normal (ULN);\n* f) Aminotransferases (AST, ALT) ≤ 2.5 × upper limit of normal (ULN);\n* g) Total bilirubin ≤ 2 × upper limit of normal (ULN);\n* h) Cardiac function: Left Ventricular Ejection Fraction (LVEF) ≥ 50% as assessed by echocardiography within 1 month prior to enrollment;\n* Able to understand the study requirements and considerations and provide informed consent to participate in the clinical study in accordance with the study requirements\n* Subjects agree to use effective contraceptive measures for at least 6 months following dendritic cell (DC) injection.\n\nExclusion Criteria:\n\n* Women who are pregnant or breastfeeding;\n* Positive for human immunodeficiency virus (HIV) antibody or syphilis antibody; positive for hepatitis B surface antigen (HBsAg), positive for hepatitis B core antibody (anti-HBc) or hepatitis B e antibody (anti-HBe) with hepatitis B virus (HBV) DNA copy number above the lower limit of detection (LLOD) or ≥ 1000 copies\u002FmL; or hepatitis C virus (HCV) RNA copy number above the LLOD;\n* Prior treatment with any dendritic cell (DC) or other immune cell therapy;\n* History of hypersensitivity to immunotherapy and related drugs, or history of severe allergic reactions;\n* Uncontrolled active infection;\n* Subjects with active autoimmune disease receiving relevant treatment; subjects with organ transplantation who are still on immunosuppressive agents; or subjects requiring long-term use of immunosuppressive agents (\\> 15 mg\u002Fday prednisone or equivalent glucocorticoid dose) and who have used them within 4 weeks prior to screening;\n* Presence of central nervous system (CNS) metastases and clinically significant CNS diseases;\n* Received systemic anti-tumor therapy within 4 weeks prior to screening;\n* Presence of residual lesions or unremoved foci on screening examinations (post-adjuvant chemotherapy \u002F post-surgery), with imaging indicating local recurrence or confirmed distant metastasis;\n* History of other active malignancies within 5 years (excluding cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, etc.);\n* Clinically significant major cardiovascular diseases including:\n* a) Symptomatic congestive heart failure\n* b) Unstable angina pectoris\n* c) Severe arrhythmia requiring pharmacotherapy\n* d) Uncontrolled hypertension\n* e) Myocardial infarction or ventricular arrhythmia within 6 months prior to screening;\n* Any other conditions deemed by the investigator to render the subject ineligible for participation in the clinical study","80 Years",{"count":108,"type":21},8,[110],"PHASE1","This study is a single-arm, open-label, single-administration dose-escalation study.",[113,29],"Solid Cancers","2026-03-15",{"date":116,"type":38},"2026-03-18",{"date":118,"type":38},"2026-02-05",{"date":120,"type":21},"2029-06-30",{"name":122,"class":123},"Shanghai Cell Therapy Group Co.,Ltd","INDUSTRY",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":130,"minAge":17,"maxAge":53,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":46},"100628842","a-single-arm-multicenter-phase-ii-clinical-study-of-camrelizumab-combined-with-famitinib-in-adjuvant-therapy-after-radical-resection-of-cervical-cancer-100628842","NCT07466901","A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer","Inclusion Criteria:\n\n1. Age: 18-75 years old, female;\n2. No prior systemic anti-tumor treatment (including chemotherapy, radiotherapy, or other investigational treatments);\n3. PD-L1 test result: CPS ≥ 1;\n4. Presence of measurable lesions at baseline according to RECIST 1.1 criteria;\n5. Pathological types: squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma;\n6. FIGO 2018 stage: IA, IB1-2, IIA1, IB3, IIA2;\n7. ECOG PS: 0-1;\n8. Expected survival period \\> 3 months;\n9. Good function of major organs, meeting the following criteria:\n\n   1. Blood routine examination (without blood transfusion or use of hematopoietic stimulating factors to correct the condition within 14 days): hemoglobin (Hb) ≥ 90g\u002FL; absolute neutrophil count (ANC) ≥ 1.5×10⁹\u002FL; platelets (PLT) ≥ 90×10⁹\u002FL;\n   2. Biochemical examination: alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 2.5×ULN (for patients with liver metastases, ≤ 5×ULN); serum total bilirubin (TBIL) ≤ 1.5×ULN (for subjects with Gilbert syndrome, ≤ 3×ULN); serum creatinine (Cr) ≤ 1.5×ULN, or creatinine clearance ≥ 60mL\u002Fmin;\n   3. Coagulation function: activated partial thromboplastin time (APTT), international normalized ratio (INR), prothrombin time (PT) ≤ 1.5×ULN;\n   4. Urinalysis shows urine protein \\\u003C 2+; if urine protein ≥ 2+, 24-hour urine protein quantification should be \\\u003C 1g;\n   5. Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) ≥ 50%.\n10. Women of childbearing age must agree to use contraceptive measures (such as intrauterine devices, contraceptives, or condoms) during the study and within 6 months after the end of the study; serum or urine pregnancy test within 7 days before enrollment must be negative, and they must be non-lactating patients; male patients must agree to use contraceptive measures during the study and within 6 months after the end of the study;\n11. Subjects voluntarily participate in this study, sign the informed consent form, have good compliance, and cooperate with follow-up.\n\nExclusion Criteria:\n\n1. Patients participating in other clinical trials at the same time, unless they are in an observational, non-interventional clinical study or the follow-up period of an interventional study;\n2. Subjects with rare histopathological types of cervical cancer, such as neuroendocrine carcinoma, sarcoma, etc.;\n3. Subjects who have had other malignant tumors within 3 years before enrollment, except for cervical cancer. Subjects with other malignant tumors that have been cured by local treatment are not excluded, such as basal or cutaneous squamous cell carcinoma, superficial bladder cancer, breast carcinoma in situ, etc.;\n4. A history of allergic reactions, hypersensitivity reactions, or intolerance to antibody-based drugs; a history of significant allergies to drugs, food, or other substances;\n5. Those with no measurable lesions or unevaluable lesions;\n6. Having received non-specific immunomodulatory therapy (such as interleukin, interferon, thymosin, tumor necrosis factor, etc., excluding IL-11 used for the treatment of thrombocytopenia) within 2 weeks before the first dose;\n7. Having received Chinese herbal medicines or proprietary Chinese medicines with anti-tumor indications within 1 week before the first dose;\n8. Having active autoimmune diseases requiring systemic treatment within the past two years;\n9. Having a history of non-infectious pneumonia requiring systemic glucocorticoid treatment, a history of pneumonia, or a current history of interstitial lung disease;\n10. Having a history of immunodeficiency; positive HIV antibody test; currently receiving long-term systemic corticosteroids or other immunosuppressants;\n11. A known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation;\n12. Subjects with evidence or history of thrombosis or obvious bleeding tendency within 2 months before the first administration of the study drug (bleeding \\> 30 mL within 2 months, with hematemesis, melena, hematochezia), hemoptysis (\\> 5 mL of fresh blood within 4 weeks);\n13. Having uncontrolled comorbidities, including but not limited to: active HBV or HCV infection; known HIV infection or AIDS history; active syphilis; active tuberculosis; active infection; uncontrolled hypertension, symptomatic cardiac insufficiency; active bleeding;\n14. Pregnant or lactating women;\n15. Active or uncontrolled severe infections (≥ CTCAE5.0 grade 2 infections), including but not limited to hospitalization due to infectious complications, bacteremia or severe pneumonia, and unexplained fever \\> 38.5℃ before the first dose;\n16. A clear history of mental disorders (including epilepsy or dementia); or other conditions that the investigator deems inappropriate for participation in the study;\n17. Patients who the investigator judges are unlikely to comply with the study procedures, restrictions, and requirements must not participate in this study.","FEMALE",{"count":132,"type":21},30,[57],"This study is a single-arm, open-label, multicenter, exploratory clinical trial aimed at observing and evaluating the efficacy and safety of camrelizumab combined with famitinib in the adjuvant treatment of cervical cancer patients after surgery.",[136,137,29],"Cervical Cancer","Radical Surgery","2026-03-09",{"date":140,"type":38},"2026-03-12",{"date":142,"type":21},"2026-04-01",{"date":144,"type":21},"2030-08-31",{"name":146,"class":45},"Jin LI",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":157,"conditions":158,"keywords":163,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":174,"locationsCount":176},"100571357","reduce-sedentary-behavior-during-cancer-treatment---the-redsedcan-study-100571357","NCT06719206","Reduce Sedentary Behavior During Cancer Treatment - the RedSedCan Study","RedSedCan","Inclusion Criteria:\n\n* Individuals diagnosed with breast, prostate, or colorectal cancer planned for or resently started neo- or adjuvant treatment (e.g. chemotherapy, radiotherapy, endocrine treatment) at the hospitals in Uppsala and Västerås, Sweden.\n\nExclusion Criteria:\n\n* Individuals diagnosed with dementia.\n* Individuals diagnosed with severe psychiatric disease.\n* Individuals with severe loss of vision, or communicative ability.\n* Individuals who cannot walk independently indoors with or without a walking aid.\n* Individuals completed treatment for other cancer diseases less than 12 months ago or not recovered from previous cancer treatment.",{"count":155,"type":21},172,[57],"Summary\n\nReducing sedentary behavior during treatment is important to reduce the risk of future health problems in individuals undergoing cancer treatment. Therefore, the goal of this project is with a multicenter randomised controlled design investigate whether a digital support intervention during ongoing neo- or adjuvant cancer treatment for breast, prostate or colon cancer is effective in reducing sedentary lifestyle and improving well-being in the short and long term.",[159,160,161,162,29],"Breast Cancer","Colorectal Cancer (CRC)","Prostate Cancer","Neoadjuvant Therapy",[164,165,166,167],"sedentary behavior","behavior change","intervention","Randomized controlled trial","2026-01-28",{"date":170,"type":38},"2026-01-30",{"date":172,"type":38},"2025-03-01",{"date":71,"type":21},{"name":175,"class":45},"Mälardalen University",2,{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":184,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":4},"100622120","adjuvant-anti-pd-1-therapy-in-resected-hepatocellular-carcinoma-100622120","NCT07379489","Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma","Efficacy of Postoperative Adjuvant PD-1 Inhibitors Guided by a Deep Learning Model: a Multicenter, Prospective Cohort Study","Inclusion Criteria:\n\n* Aged between 18 and 75;\n* achieved complete tumor resection;\n* histological verification of HCC;\n* liver function classified as Child-Pugh grade A or B;\n* No other serious systemic disease or organ dysfunction.\n\nExclusion Criteria:\n\n* history of other malignancies or recurrent HCC;\n* extrahepatic metastasis;\n* prior treatments for HCC;\n* ongoing severe postoperative complications;\n* mixed or other types of liver cancer;\n* received other adjuvant therapy.",{"count":185,"type":21},300,"Early hepatocellular carcinoma (HCC) recurrence (driven by residual tumors) and late recurrence (driven by de novo tumors) exhibit distinct biological behaviors, suggesting differential therapeutic vulnerabilities. The beneficiaries of adjuvant PD-1 inhibitors (aPD-1) and their efficacy across these temporally divergent recurrence patterns remains unestablished.",[188,29,189,190],"HCC","Recurrence","Immune Checkpoint Inhibitor","2026-01-23",{"date":170,"type":38},{"date":194,"type":21},"2026-01-31",{"date":196,"type":21},"2031-12-31",{"name":198,"class":45},"Tongji Hospital",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":130,"minAge":17,"maxAge":206,"enrollmentInfo":207,"targetDuration":4,"studyType":22,"phases":209,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":46},"100594432","phase-3-cdk46-inhibitors-combined-with-standard-adjuvant-endocrine-therapy-in-high-risk-hrher2-early-breast-cancer-patientschess-100594432","NCT07019363","CDK4\u002F6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+\u002FHER2+ Early Breast Cancer Patients(CHESS)","A Study on the Efficacy and Safety of CDK4\u002F6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+\u002FHER2+ Early Breast Cancer Patients Who Have Completed Adjuvant Anti-HER2 Targeted Therapy\"","Inclusion Criteria:\n\n1. Females aged ≥18 and ≤70 years.\n2. ECOG systemic status grade 0 to 1.\n3. Histologically confirmed invasive HR+\u002FHER2+ breast cancer (Specific definition: breast cancer patients whose estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) are all determined to be positive by pathologic testing. Specifically: ER positive: IHC\\>10%, PR positive: IHC\\>10%, HER2 positive: IHC+++ or IHC++ but amplified by FISH.\n4. Early-stage breast cancer after radical mastectomy with postoperative pathology consistent with TNM staging of ≥pN1 ; or postoperative pathology suggestive of non-pCR after neoadjuvant therapy; or postoperative pathology suggestive of pCR after neoadjuvant therapy but with clinical staging consistent with cT4 or N3 before neoadjuvant therapy\n5. Within 1 year of completion of adjuvant anti-HER2 targeted therapy: anti-HER2 targeted therapy includes trastuzumab-based therapy, and\u002For T-DM1 therapy, and\u002For TKI therapy.\n6. The function of major organs is basically normal, and the following conditions are met: ① The criteria for routine blood tests need to be met: HB ≥ 90g\u002FL (no blood transfusion within 14 days); ANC ≥ 1.5 × 109\u002FL; PLT ≥ 75 × 109\u002FL; ② The biochemical tests need to be met as follows: TBIL ≤ 1.5 × ULN (the upper limit of normal value); ALT and AST ≤ 3 × ULN; serum Cr ≤ 1 × ULN, and endogenous creatinine clearance \\> 50 ml\u002Fmin (Cockcroft-Gault formula).\n7. Female subjects of childbearing potential are required to use a medically approved form of contraception during study treatment, and for at least 3 months after the last dose of study drug.\n8. Subjects voluntarily enrolled in the study, signed an informed consent form, were compliant, and cooperated with follow-up visits.\n\nExclusion Criteria:\n\n1. Bilateral breast cancer;\n2. Metastasis to any site;\n3. Taking food or medications that are strong inhibitors or inducers of CYP3\u002F4.\n\n   1. Strong inhibitors of CYP3\u002F4 include: boceprevir, clarithromycin, konifactam, delavirdine, indinavir, itraconazole, ketoconazole, ritonavir, mibefradil, miconazole, fazodone, nelfinavir, propoxiconazole, ritonavir, saquinavir, naloxone, telaprevir, telithromycin, voriconazole, grapefruit, grapefruit juice, or grapefruit containing foods.\n   2. Strong inducers of CYP3\u002F4 including carbamazepine, phenytoin, pramipexole, rifampin, and St. John's wort.\n4. History of clinically significant or uncontrolled cardiac disease including congestive heart failure, angina pectoris, myocardial infarction within the last 6 months, or ventricular arrhythmia;\n5. other malignancy within the previous 5 years, excluding cured carcinoma in situ of the cervix, basal cell carcinoma of the skin, or squamous cell carcinoma of the skin;\n6. Pregnant or lactating women, women of childbearing age who are unable to use effective contraception;\n7. Patients who are concurrently enrolled in other clinical trials;\n8. severe or uncontrolled infection;\n9. Patients with known active HBV or HCV infection or Hepatitis B DNA ≥500, or chronic stage with abnormal liver function;\n10. Those with a history of psychotropic substance abuse that cannot be stopped or those with psychiatric disorders;\n11. Patients who, in the judgment of the investigator, are not suitable for participation in this study.","70 Years",{"count":208,"type":21},1903,[210],"PHASE3","This study is a prospective, open-label, multicenter, randomized controlled Phase III clinical trial. Building upon anti-HER2 targeted therapy combined with endocrine therapy, the addition of CDK4\u002F6 inhibitors has demonstrated greater clinical benefits for advanced TPBC patients. This study aims to investigate the efficacy and safety of CDK4\u002F6 inhibitor combination with standard adjuvant endocrine therapy in HR+\u002FHER2+ early breast cancer patients.",[159,29],"2026-01-16",{"date":215,"type":38},"2026-01-21",{"date":217,"type":38},"2025-06-15",{"date":219,"type":21},"2033-04-15",{"name":221,"class":45},"Fudan University",{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":130,"minAge":17,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":22,"phases":231,"briefSummary":232,"conditions":233,"keywords":236,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":4},"100600720","phase-2-dalpiciclib-as-adjuvant-therapy-for-hr-positiveher2-negative-early-stage-patients-100600720","NCT07101159","Dalpiciclib as Adjuvant Therapy for HR-positive\u002FHER2-negative Early-stage Patients","Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy in Early-stage HR-positive\u002FHER2-negative Breast Cancer: a Multicenter, Prospective Clinical Study","Inclusion Criteria:\n\n* Female breast cancer patients aged ≥ 18 years, who are postmenopausal or premenopausal\u002Fperimenopausal;\n* Histologically confirmed HR-positive, HER2-negative early-stage breast cancer (immunohistochemical detection shows ER ≥ 10% and\u002For PR ≥ 10%, HER2 0-1+ or HER2 ++ but negative and non-amplified by FISH or CISH detection);\n* Histologically confirmed invasive breast cancer with postoperative pathological stage II-III;\n* Patients with or without prior neoadjuvant chemotherapy or adjuvant chemotherapy are eligible for enrollment;\n* The maximum time from surgery to enrollment does not exceed 12 months;\n* Patients receiving radiotherapy must have recovered from acute radiation reactions, with a washout period of at least 14 days from the end of radiotherapy to enrollment;\n* Patients who received previous chemotherapy must have recovered from acute adverse reactions of chemotherapy (graded ≤ 1 according to \\[CTCAE\\]) before enrollment, except for alopecia or grade 2 peripheral neuropathy. There must be a washout period of at least 21 days from the last chemotherapy administration to enrollment;\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;\n* The main organ function levels must meet the following requirements: Blood routine: Neutrophil count (ANC) ≥ 1.5×10⁹\u002FL; Platelet count (PLT) ≥ 90×10⁹\u002FL; Hemoglobin (Hb) ≥ 90 g\u002FL;Blood biochemistry: Total bilirubin (TBIL) ≤ 2.5×ULN; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 1.5×ULN; Alkaline phosphatase ≤ 2.5×ULN; Blood urea nitrogen (BUN) and creatinine (Cr) ≤ 1.5×ULN;\n* 12-lead electrocardiogram: Fridericia-corrected QT interval (QTcF) \\\u003C 470 ms in females (QTcF calculation formula: QTcF = QT\u002F(RR\\^1\u002F3));\n* Voluntarily participate in this study, sign the informed consent, have good compliance and are willing to cooperate with follow-up.\n\nExclusion Criteria:\n\n* Stage IV breast cancer, recurrent or metastatic breast cancer, or inflammatory breast cancer;\n* A history of any malignant tumor, or having received anti-tumor treatment or radiotherapy for any malignant tumor in the past, excluding cured malignant tumors such as carcinoma in situ of the cervix, basal cell carcinoma or squamous cell carcinoma of the skin;\n* Concurrent participation in other clinical trials;\n* Having received blood transfusion or treatment with colony-stimulating factors, etc. within 2 weeks before enrollment;\n* Known history of allergy to the components of the drugs in this protocol;\n* History of immunodeficiency, including positive HIV test, or suffering from other acquired or congenital immunodeficiency diseases, or having a history of organ transplantation;\n* A history of any heart disease, including: angina pectoris; arrhythmia requiring drug treatment or with clinical significance; myocardial infarction; heart failure; any other heart disease judged by the researcher as unsuitable for participating in this trial;\n* Pregnant or lactating female patients;\n* Any other conditions that the researcher deems make the subject unsuitable for participating in this study.",{"count":230,"type":21},200,[24],"This study aims to evaluate the efficacy and safety of adjuvant endocrine therapy combined with dalpiciclib at different doses and durations in patients with hormone receptor (HR)-positive, HER2-negative early-stage breast cancer.\n\nIt is a multicenter, prospective clinical study. All enrolled patients will receive either dalpiciclib 125 mg for 2 years or dalpiciclib 100 mg for 3 years, in combination with standard endocrine therapy.\n\nThe primary endpoint is 3-year invasive disease-free survival (iDFS).",[234,29,235],"Early Breast Cancer","Hormone Receptor Positive \u002F HER2-negative Breast Cancer",[237,238,239],"dalpiciclib","hormone receptor positive\u002FHER2-negative breast cancer","early breast cancer","2025-08-01",{"date":242,"type":38},"2025-08-03",{"date":244,"type":21},"2025-09",{"date":246,"type":21},"2031-12",{"name":248,"class":249},"Fujian Cancer Hospital","OTHER_GOV",{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":257,"targetDuration":4,"studyType":22,"phases":258,"briefSummary":259,"conditions":260,"keywords":264,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":270,"leadSponsor":272,"locationsCount":4},"100600050","pucotenlimab-combined-with-chemotherapy-as-perioperative-treatment-for-locally-advanced-gastroesophageal-junction-carcinoma-100600050","NCT07092449","Pucotenlimab Combined With Chemotherapy as Perioperative Treatment for Locally Advanced Gastroesophageal Junction Carcinoma","Pucotenlimab Combined With Chemotherapy (Nab-Paclitaxel + Tegafur + Carboplatin) in the Perioperative Treatment of Locally Advanced Gastroesophageal Junction Tumors, A Multi-center Prospective Study","Inclusion Criteria:\n\n1. Informed Consent Provide written informed consent for the clinical study and biobank before any study-related procedures.\n2. Age and Gender Male or female patients aged 18 to 75 years.\n3. Disease Diagnosis Histologically confirmed resectable locally advanced gastroesophageal junction tumor.\n\n   cTNM staging of cT2N+M0 or cT3-4bNxM0 based on endoscopic ultrasonography, contrast-enhanced CT\u002FMRI (with endoscopic ultrasonography, diagnostic laparoscopy, or PET-CT as needed), corresponding to locally advanced gastroesophageal junction tumor per AJCC 9th edition, and deemed resectable by the investigator.\n4. Prior Treatment History No prior systemic therapy for the current disease, including surgery, anti-tumor radiotherapy\u002Fchemotherapy, immunotherapy, etc.\n5. Surgical Eligibility Agree to receive radical surgery and have no surgical contraindications as judged by surgeons.\n6. Target Lesion Assessment At least one lesion (untreated with radiotherapy) meets RECIST 1.1 target lesion (TL) criteria.\n\n   Tumor assessment must be performed via CT or MRI within 28 days before treatment.\n7. Performance Status ECOG score of 0-1.\n8. Life Expectancy Expected survival ≥ 3 months.\n9. Organ Function Requirements\n\nLaboratory parameters must meet the following within 14 days:\n\nAbsolute neutrophil count (ANC) ≥ 1.5×10⁹\u002FL (without granulocyte colony-stimulating factor use).\n\nPlatelets ≥ 100×10⁹\u002FL (without blood transfusion). Hemoglobin \\> 9 g\u002FdL (without blood transfusion or erythropoietin use). Total bilirubin ≤ 1.5×ULN; if total bilirubin \\> 1.5×ULN, direct bilirubin must be ≤ ULN.\n\nAST and ALT ≤ 2.5×ULN. Serum creatinine ≤ 1.5×ULN or creatinine clearance (Cockcroft-Gault formula) ≥ 60 mL\u002Fmin.\n\nCoagulation function: INR or PT ≤ 1.5×ULN. No severe thyroid dysfunction (as judged by the investigator). Cardiac function: NYHA class \\\u003C 3; left ventricular ejection fraction ≥ 50%. 10. Contraceptive Measures and Pregnancy Testing\n\nFor female subjects of childbearing potential:\n\nNegative urine or serum pregnancy test within 3 days before the first study drug administration (Cycle 1, Day 1). If urine test is inconclusive, a blood test is required.\n\nNon-childbearing potential is defined as postmenopausal for ≥1 year, surgically sterilized, or having undergone hysterectomy.\n\nAll subjects (male and female) at risk of conception must use contraception with an annual failure rate \\\u003C 1% throughout treatment and for 120 days after the last study drug administration (or 180 days after the last chemotherapy dose).\n\nExclusion Criteria:\n\n1. Diagnosed with malignant diseases other than gastroesophageal junction tumors within 5 years before the first administration (excluding radically treated basal cell carcinoma of the skin, cutaneous squamous cell carcinoma, and\u002For carcinoma in situ after radical resection);\n2. Known endoscopic evidence of active bleeding in the lesion;\n3. Known evidence of distant metastasis;\n4. Currently participating in therapeutic interventions of an interventional clinical study, or having received other drug therapies for malignant gastroesophageal junction tumors within 4 weeks before the first administration;\n5. Having previously received the following therapies: anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs, or drugs targeting another stimulatory or co-inhibitory T-cell receptor (including but not limited to CTLA-4, OX-40, CD137, etc.), or chemotherapy (including but not limited to S-1);\n6. Having received systemic treatment with Chinese patent medicines with anti-tumor indications or drugs with immunomodulatory effects (including thymosin, interferon, interleukin, excluding those used locally to control pleural effusion) within 2 weeks before the first administration;\n7. Having had active autoimmune diseases requiring systemic treatment (such as disease-modifying drugs, glucocorticoids or immunosuppressants) within 2 years before the first administration. Alternative therapies (such as thyroxine, insulin, or physiological glucocorticoids for adrenal or pituitary insufficiency, etc.) are not considered systemic treatment;\n8. Receiving systemic glucocorticoid therapy (excluding nasal spray, inhaled or other forms of topical glucocorticoids) or any other form of immunosuppressive therapy within 7 days before the first administration of the study; Note: The use of physiological doses of glucocorticoids (≤ 10 mg\u002Fday of prednisone or equivalent drugs) is allowed;\n9. Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation;\n10. Known history of allergy to putlizumab, chemotherapeutic drugs used in this study or their components;\n11. Before starting treatment, not having fully recovered from toxicities and\u002For complications caused by any interventions (i.e., ≤ Grade 1 or returning to baseline, excluding fatigue or alopecia);\n12. Known history of human immunodeficiency virus (HIV) infection (i.e., positive for HIV 1\u002F2 antibodies);\n13. Untreated active hepatitis B (defined as positive HBsAg with HBV-DNA copy number greater than the upper limit of normal of the laboratory in the research center);\n\nNote: Hepatitis B subjects meeting the following criteria can also be enrolled:\n\n1\\) HBV viral load \\\u003C 1000 copies\u002Fml (200 IU\u002Fml) before the first administration, and subjects should receive anti-HBV treatment during the entire study period of chemotherapeutic drug treatment to avoid viral reactivation; 14. Subjects with active HCV infection (HCV antibody positive and HCV-RNA level above the lower limit of detection); 15. Having received a live vaccine within 30 days before the first administration (Cycle 1, Day 1); Note: Administration of inactivated viral vaccines for seasonal influenza within 30 days before the first administration is allowed; however, intranasal attenuated live influenza vaccines are not allowed; 16. Pregnant or lactating women; 17. Having any severe or uncontrollable systemic diseases, such as:\n\n1. Significant and severely symptomatic abnormalities in resting electrocardiogram in terms of rhythm, conduction or morphology, such as complete left bundle branch block, second-degree or higher atrioventricular block, ventricular arrhythmias or atrial fibrillation;\n2. Unstable angina pectoris, congestive heart failure, chronic heart failure with New York Heart Association (NYHA) class ≥ 2;\n3. Any arterial thrombosis, embolism or ischemia occurring within 6 months before enrollment, such as myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack;\n4. Poorly controlled hypertension with medication;\n5. A history of non-infectious pneumonia requiring glucocorticoid treatment within 1 year before the first administration, or currently having clinically active interstitial lung disease;\n6. Active pulmonary tuberculosis;\n7. Having active or uncontrolled infections requiring systemic treatment;\n8. Having clinically active diverticulitis, abdominal abscess, intestinal obstruction;\n9. Liver diseases such as decompensated liver disease, acute or chronic active hepatitis;\n10. Poorly controlled diabetes;\n11. Patients with mental disorders who cannot cooperate with treatment; 18. Known dihydropyrimidine dehydrogenase deficiency; 19. Patients with gastrointestinal obstruction, or physiological dysfunction or malabsorption syndrome; Evidence of medical history, diseases, treatments or abnormal laboratory test values that may interfere with the study results, prevent the subjects from participating in the study throughout the process, or other situations that the researcher deems unsuitable for enrollment, or the researcher deems that there are other potential risks that make the subject unsuitable for participating in this study.",{"count":132,"type":21},[57],"This study is a prospective, multicenter, single-arm clinical trial.\n\nThe study intends to enroll patients with pathologically or cytologically confirmed resectable locally advanced gastroesophageal junction tumors (cT2N+M0 and cT3-4bNxM0) who have not received prior systemic therapy. After signing the informed consent and being screened to meet the inclusion and exclusion criteria, patients will receive 3 cycles of Pucotenlimab combined with chemotherapy (Nab-Paclitaxel + Tegafur + Carboplatin). Preoperative imaging evaluations will be performed 3 to 6 weeks after the final dose administration to assess the efficacy of neoadjuvant therapy and the feasibility of radical resection. Efficacy evaluation will be performed after radical surgery for locally advanced gastroesophageal junction tumors.",[261,262,263,29],"Gastroesophageal Junction","Gastric \u002F Gastroesophageal Junction Adenocarcinoma","Neoadjuvant Chemoimmunotherapy",[265],"A Prospective Observational Study of Putilimab Combined with Chemotherapy in the Perioperative Treatment of Locally Advanced Gastroesophageal Junction Tumors","2025-07-22",{"date":268,"type":38},"2025-07-29",{"date":240,"type":21},{"date":271,"type":21},"2027-12-31",{"name":273,"class":45},"Tang-Du Hospital",{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":11,"sex":130,"minAge":18,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":22,"phases":284,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":291,"leadSponsor":293,"locationsCount":4},"100593370","phase-3-chemo-free-in-older-65-node-positive-erher2--breast-cancer-100593370","NCT07005557","Chemo-free in Older (≥65) Node-Positive ER+\u002FHER2- Breast Cancer","Study Evaluating Node-positive, ER+\u002FHER2- In Older (≥65 Years) Breast Cancer Patients for Chemotherapy Exemption: A Randomized, Open-label, Multicenter Phase III Clinical Trial","SENIOR","Inclusion Criteria:\n\n-1. Age: Female patients aged ≥65 years. 2. Disease Status: Histologically confirmed early-stage breast cancer after surgery with ER expression ≥50% AND one of the following:\n\n1. ≥4 positive lymph nodes\n2. 1-3 positive lymph nodes plus at least one of the following high-risk features: i. High-risk multigene assay result ii. Primary tumor size \\>2 cm iii. Histologic grade 3 iv. Lymphovascular invasion (LVI) positive v. Ki-67 \\>20% 3. Treatment Acceptance: Willing to receive adjuvant CDK4\u002F6 inhibitor therapy. 4. Performance Status: ECOG score 0-2. 5. Adequate Organ Function:\n\na) Hematology (within 14 days, no transfusion): i. Hemoglobin (Hb) ≥90 g\u002FL ii. Absolute neutrophil count (ANC) ≥1.5×10⁹\u002FL iii. Platelets (PLT) ≥100×10⁹\u002FL b) Biochemistry: i. Total bilirubin (TBIL) ≤1.5×ULN ii. ALT\u002FAST ≤3×ULN iii. Serum creatinine (Cr) ≤1×ULN iv. Estimated creatinine clearance (CrCl) \\>50 mL\u002Fmin (Cockcroft-Gault formula) 6. Consent \\& Compliance: Willing to participate, sign informed consent, and comply with follow-up.\n\nExclusion Criteria:\n\n* 1\\. Patients who have received neoadjuvant therapy (including chemotherapy, targeted therapy, radiotherapy, or endocrine therapy).\n\n  2\\. Bilateral breast cancer. 3. History of other malignancies, except: Cured basal cell carcinoma of the skin； Carcinoma in situ of the cervix 4. Distant metastasis (any site). 5. Any T4 lesion (UICC 1987 TNM staging), including: Skin invasion; Fixed mass adherence; Inflammatory breast cancer 6. Concurrent participation in other clinical trials. 7. Severe organ dysfunction (cardiac, pulmonary, hepatic, or renal), including:\n\n  a) LVEF \\\u003C50% (by echocardiography) b) Major cardiovascular\u002Fcerebrovascular events within 6 months before randomization: i. Unstable angina ii. Chronic heart failure iii. Uncontrolled hypertension (\\>150\u002F90 mmHg) iv. Myocardial infarction or stroke c) Poorly controlled diabetes mellitus d) Severe hypertension 8. Known allergy to taxane-based drugs or their excipients. 9. Severe or uncontrolled infections. 10. History of psychoactive drug abuse (unable to abstain) or psychiatric disorders.\n\n  11\\. Patients deemed ineligible by investigator assessment. 12. Refusal to receive adjuvant CDK4\u002F6 inhibitor therapy.",{"count":283,"type":21},1244,[210],"This study is a prospective, open-label, multicenter, randomized controlled Phase III clinical trial. Based on the use of CDK4\u002F6 inhibitors in endocrine-sensitive luminal-type (ER+\u002FHER2-) breast cancer, it aims to explore the possibility of chemotherapy exemption in elderly patients (aged \\>65 years) with lymph node-positive, HR+\u002FHER2- breast cancer.",[159,29],"2025-06-03",{"date":289,"type":38},"2025-06-05",{"date":217,"type":21},{"date":292,"type":21},"2035-05-15",{"name":221,"class":45},{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":303,"conditions":304,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":46},"100589161","prognostic-impact-of-adjuvant-therapy-in-primary-hepatic-sarcomatoid-carcinoma-100589161","NCT06950814","Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma","Prognostic Impact of Adjuvant Therapy Following Surgical Resection in Primary Hepatic Sarcomatoid Carcinoma: A Retrospective Cohort Study","Inclusion Criteria:\n\n1. patients who underwent liver resection\n2. patients' postoperative paraffin pathology and immunohistochemistry results were reviewed to identify those diagnosed with PHSC\n\nExclusion Criteria:\n\n1. patients who received other anti-tumor treatments before surgery, such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), radiation therapy (RT), and systemic therapy;\n2. patients diagnosed with other specific types of sarcomas;\n3. patients with concurrent other malignancies during the course of PHSC;\n4. patients who were lost to follow-up or lacked essential clinical data.",{"count":302,"type":21},50,"In recent years, researchers have conducted extensive studies on adjuvant therapy following surgical resection of liver cancer, exploring its potential benefits and seeking effective treatment strategies. Given the rarity and high aggressiveness of primary hepatic sarcomatoid carcinoma, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines. Therefore, we conducted a single-center retrospective study to assess the potential benefits of postoperative adjuvant therapy for patients of primary hepatic sarcomatoid carcinoma.",[305,306,29],"Sarcomatoid Carcinoma","Liver Cancer","2025-04-22",{"date":309,"type":38},"2025-04-30",{"date":311,"type":38},"2025-04-05",{"date":313,"type":21},"2025-05-05",{"name":315,"class":45},"West China Hospital",{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":323,"targetDuration":4,"studyType":22,"phases":325,"briefSummary":326,"conditions":327,"keywords":329,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":46},"100542537","phase-1-neoantigen-vaccine-plus-anti-pd1-and-chemotherapy-as-an-adjuvant-therapy-for-pancreatic-cancer-100542537","NCT06344156","Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer","Adjuvant Therapy of Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy in Patients With Resected Pancreatic Cancer","Inclusion Criteria:\n\n1. Age ≥18 years and age ≤75 years.\n2. ECOG score 0-1.\n3. Patients with histologically confirmed pancreatic ductal adenocarcinoma, R0 resection, stage I-III, not receiving neoadjuvant therapy.\n4. Adequate bone marrow and organ function:\n5. Patients of childbearing potential must take appropriate precautions prior to enrollment and during the study.\n6. Signed informed consent.\n7. Ability to comply with the study protocol and follow-up.\n\nExclusion Criteria:\n\n1. Received antitumor chemotherapy, radiation therapy, or immunotherapy within 2 weeks prior to first vaccination.\n2. The patient has a history of other tumors, except for cervical cancer in situ, treated squamous cell carcinoma or urothelial tumors (Ta and TIS), or other malignancies that have been treated with curative intent (at least 5 years prior to enrollment).\n3. Uncontrollable comorbidities, including but not limited to active bacterial or fungal infections, symptomatic congestive heart failure, unstable angina, arrhythmias.\n4. HIV infection or active hepatitis B (HBV DNA≥500IU\u002Fml), hepatitis C.\n5. Uncontrolled coronary artery disease or asthma, uncontrolled cerebrovascular disease, or other conditions deemed ineligible by the investigator.\n6. Uncontrollable comorbidities, including but not limited to active bacterial or fungal infections, congestive heart failure, unstable angina, arrhythmias, etc;\n7. Patients with autoimmune diseases or immunodeficiencies being treated with immunosuppressive drugs.\n8. Pregnant or lactating women.\n9. Vaccination with other preventive vaccines within 4 weeks before the first administration or planned during the study period, including within 8 weeks after the last vaccination.\n10. Those who have had a severe allergic reaction to vaccines for other infectious diseases in the past.\n11. Those who may be allergic to the investigational product or any of its excipients.\n12. Substance abuse or inability to undergo immunotherapy due to clinical, psychological, or social factors.\n13. Significant weight loss (≥10%) within 6 weeks prior to enrollment.\n14. Any uncertain factors that may affect patient safety or compliance.",{"count":324,"type":21},43,[110],"The aim of this single center, single arm and prospective study is to explore the safety and efficacy of Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy in postoperative adjuvant treatment of Pancreatic Cancer",[328,29],"Pancreatic Cancer",[328,330,32,331,332],"Neoantigen","Safety","Clinical efficacy","2025-02-25",{"date":335,"type":38},"2025-02-28",{"date":337,"type":38},"2024-04-01",{"date":339,"type":21},"2027-04-01",{"name":341,"class":45},"Sichuan University",{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":351,"conditions":352,"keywords":357,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":46},"100563845","retrospective-observational-study-of-the-safety-and-toxicity-management-of-abemaciclib-in-combination-with-adjuvant-hormone-therapy-in-patients-with-rh-her2-nonoveramplified-breast-cancer-real-life-data-monarche29-100563845","NCT06621459","Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Hormone Therapy in Patients with RH+ ,HER2-nonoveramplified Breast Cancer, Real-life Data (MONARCHE29)","Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Hormone Therapy in Patients with RH+ ,HER2-nonoveramplified Breast Cancer, Real-life Data","MONARCHE29","Inclusion Criteria:\n\n* Adult patient\n* Patient who has received adjuvant ABEMACICLIB in combination with hormone therapy\n* Patient with localized RH+ HER2 non-amplified breast cancer and eligible for treatment with ABEMACICLIB according to the recommendations of the MA (Marketing Authorization) as defined below:\n\n  * 4 ipsilateral positive axillary lymph nodes OR\n\n    1. to 3 ipsilateral positive axillary lymph node(s) with at least one of the following two criteria: histological grade 3 or primary tumor size ≥5 cm\n\nExclusion Criteria:\n\n* Patients under legal protection (guardianship, trusteeship, etc.)\n* Refusal to participate",{"count":132,"type":21},"Overall survival at 8 years under treatment for localized hormone-dependent breast cancer is 93.3% (1). Adjuvant therapy, especially hormone therapy, helps reduce the risk of recurrence.\n\nHowever, the risk of relapse remains significant, estimated at around 20% according to studies. The SOFT study, which compares the type of hormone therapy used in premenopausal patients, estimates a relapse risk of 21.1% at 8 years (1), especially when there is initial lymph node involvement. In fact, in cases of lymph node involvement, the cumulative relapse rate at 10 years after stopping hormone therapy ranges between 19% and 36% (2), and the risk of death from breast cancer 20 years after stopping hormone therapy is estimated at 28% to 49% (2).\n\nCDK4\u002F6 inhibitors first demonstrated their efficacy at the metastatic stage. Abemaciclib improved median survival to 46.7 months compared to a median of 37.3 months with hormone therapy alone (Monarch 2 (3) and Monarch 3 (4)). Palbociclib showed in PALOMA-2 (5) an improvement in progression-free survival (24.8 months versus 14.5 months) without an improvement in overall survival. Ribociclib, in turn, demonstrated in MONALEESA 2 (6) an improvement in PFS (25.3 months versus 16 months) and in overall survival (63.9 months versus 51.4 months). These treatments have become the standard first-line treatment for patients with RH+ HER2 non-amplified breast cancer.\n\nGiven the results in advanced lines, CDK4\u002F6 inhibitors have been the subject of studies in localized breast cancer, particularly in this high-risk population where the recurrence rate remains significant.\n\nThe MONARCH-E study, published on September 20, 2020 (7), led to the approval of Abemaciclib by European authorities at the time of the initial publication (median follow-up of 15.4 months) and to reimbursement starting in May 2023 after a second interim analysis (8) in this at-risk population, with a 5.6% reduction in relapse risk after 42 months of follow-up compared to hormone therapy alone.\n\nIt is crucial to clearly define the at-risk population in order to offer them treatment intensification while maintaining a satisfactory quality of life. The group benefiting from Abemaciclib presented grade III toxicity in 43% of cases and grade IV toxicity in 2.5%.\n\nReal-world data are needed to better understand the management and toxicity of this treatment.",[353,354,29,355,356],"Brest Cancer","Abemaciclib","Antineoplastic Combined Chemotherapy Protocols","Breast Neoplasms",[354,29,355,159,358,359],"Real-life","Real Word Data","2024-09-27",{"date":362,"type":38},"2024-10-01",{"date":364,"type":21},"2024-09-26",{"date":366,"type":21},"2025-10-31",{"name":368,"class":45},"University Hospital, Brest",{"id":370,"slug":371,"hasResults":11,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":376,"targetDuration":4,"studyType":22,"phases":378,"briefSummary":379,"conditions":380,"keywords":382,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":46},"100560758","postoperative-adjuvant-therapy-of-donafenib-for-hepatocellular-carcinoma-100560758","NCT06581315","Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma","Efficacy and Safety of Donafenib as Adjuvant Therapy for Postoperative Patients With High-Risk Recurrent Hepatocellular Carcinoma: A Multicenter, Randomized Controlled Study","Inclusion Criteria:\n\n* Participants underwent radical resection of hepatocellular carcinoma 4 weeks before randomization\n* High Risk of recurrence as assessed by tumor characteristics\n* Without any anti-tumor therapy before surgery, except preoperative TACE therapy, traditional Chinese medicine therapy and interferon therapy\n* Child-Pugh Class A statu\n* ECOG Performance Status of 0 or 1\n* CT\u002FMR confirmed no recurrence or metastasis at ≥4 weeks after surgery\n* Expected survival time of no less than 3 months\n\nExclusion Criteria:\n\n* Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC\n* Evidence of residual or a history of spontaneous tumor rupture\n* Recurrent HCC\n* Prior received Liver transplantation\n* Prior anti tumor therapy for treatment of HCC (including sorafenib or any other molecular therapy, anti-PD-1 antibody and other immunotherapies, FOLFOX systemic chemotherapy) is excluded\n* AFP does not return to normal 4 weeks after operation",{"count":377,"type":21},204,[57],"This study aims to evaluate the efficacy and safety of donafenib as adjuvant therapy for postoperative patients with high-risk recurrent Hepatocellular Carcinoma. This is a multicenter, randomized controlled study.",[381,29],"Hepatocellular Carcinoma",[381,29],"2024-08-30",{"date":385,"type":38},"2024-09-03",{"date":387,"type":21},"2024-08-28",{"date":389,"type":21},"2032-08-30",{"name":391,"class":45},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":393,"slug":394,"hasResults":11,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":399,"targetDuration":4,"studyType":22,"phases":401,"briefSummary":402,"conditions":403,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":408,"leadSponsor":410,"locationsCount":46},"100543857","irinotecan-liposome-combined-with-oxaliplatin-and-tegafur-as-adjuvant-therapy-for-pancreatic-cancer-100543857","NCT06361316","Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer","Efficacy and Safety of Irinotecan Liposome Injection Combined With Oxaliplatin and Tegafur (NASOX) in Adjuvant Chemotherapy for Pancreatic Cancer","Inclusion Criteria:\n\n1. ECOG performance status 0 or 1.\n2. Histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1).\n3. ECOG performance status 0 or 1.\n4. Life expectancy of greater than or equal to 6 months.\n5. Able and willing to provide a written informed consent.\n\nExclusion Criteria:\n\n1. Patients who cannot eat orally and have gastric emptying disorder after surgery;\n2. Patients with moderate diarrhea: diarrhea ≥4 times per day; the moderate and severe effluents from stoma increased; Or diarrhea that limits activities of daily living;\n3. Patients who cannot eat orally and have gastric emptying disorder after surgery;\n4. Patients who cannot eat orally and have gastric emptying disorder after surgery;",{"count":400,"type":21},53,[57],"The purpose of this study is to evaluate the efficacy and safety of irinotecan liposome injection in combined with oxaliplatin plus tegafur (NASOX) for postoperative adjuvant chemotherapy for pancreatic cancer.",[328,29],"2024-04-08",{"date":406,"type":38},"2024-04-11",{"date":404,"type":21},{"date":409,"type":21},"2028-07-31",{"name":411,"class":45},"Kuirong Jiang",{"id":413,"slug":414,"hasResults":11,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":4,"eligibilityCriteria":418,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":419,"targetDuration":4,"studyType":22,"phases":421,"briefSummary":422,"conditions":423,"keywords":425,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":46},"100520420","phase-2-perioperative-tislelizumab-plus-chemotherapy-for-resectable-thoracic-oesophageal-squamous-cell-carcinoma-100520420","NCT06056336","Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma","Perioperative Immunoagent (Tislelizumab) Plus Chemotherapy for Locally Advanced Resectable Thoracic Oesophageal Squamous Cell Carcinoma Trail:A Prospective Single-arm,Phase II Study (PILOT Trail)","Inclusion Criteria:\n\n1. The patient volunteers to participate in the study, signs a consent form, has good compliance, and obeys the follow-up, and is willing and able to follow the protocol during the study;\n2. Histologically-confirmed squamous cell carcinoma; tumors of the esophagus are located in the thoracic cavity;\n3. Have not received systemic and local treatment for esophageal cancer;\n4. Pre-treatment staging as cT1b-3N1-3M0 or T3N0M0, American Joint Committee on Cancer (AJCC)\u002FUnion for International Cancer Control (UICC) 8th edition;\n5. Male or female, aged ≥18 and ≤75 years;\n6. The Eastern Cooperative Oncology Group (ECOG) performance status (PS) score is 0 -1;\n7. R0 resection is expected;\n8. Adequate cardiac function. All patients should perform electrocardiogram (ECG), and those with a cardiac history or ECG abnormality should perform echocardiography with the left ventricular ejection fraction \\>50%;\n9. Adequate respiratory function with forced expiratory volume in 1 second (FEV1) ≥ 1.2 L, FEV1% ≥ 50% and lung diffusing capacity for carbon monoxide (DLCO) ≥ 50% shown in pulmonary function tests;\n10. Adequate bone marrow function (white blood cells \\> 4×109\u002FL, neutrophil \\> 1.5 ×109\u002FL, hemoglobin \\> 90g\u002FL, platelets \\> 100×109\u002FL). Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 3× upper level of normal (ULN);\n11. Adequate liver function (total bilirubin \\\u003C1.5× ULN, AST and ALT \\\u003C2.5× ULN);\n12. Adequate renal function (glomerular filtration rate (GFR) \\>60 mL\u002Fmin; serum creatinine (SCr) ≤120 μmol\u002FL\\];\n13. Fertile female subjects are required to have a negative serum or urine pregnancy test no later than 72 hours before starting the study drug administration, and to use effective contraception (such as an IUD, contraceptive pill, or condom) during the trial period and for at least 3 months after the last dose; For male subjects whose partners are women of reproductive age, effective contraception should be used during the trial period and within 3 months after the last dose.\n\nExclusion Criteria:\n\n1. Unresectable factors, including those who are unresectable for tumor reasons or have surgical contraindications, or who refuse surgery;\n2. Patients with supraclavicular lymph node metastasis;\n3. Poor nutritional status, BMI\\\u003C18.5Kg\u002Fm2; Patients could continue to be considered for enrollment if corrected with symptomatic nutritional support before enrollment and after assessment by the principal investigator\n4. Allergy to any drugs;\n5. Have received or are receiving any of the following treatments; a) any radiotherapy, chemotherapy or other antineoplastic drugs directed at the tumour; b) being treated with an immunosuppressive drug or systemic hormone for immunosuppression (at a dose of \\>10mg\u002F day of prednisone or equivalent) within 2 weeks before the first dose of the study drug; Inhaled or topical steroids and corticosteroid replacement at doses \\>10mg\u002F day of prednisone or equivalent were allowed in the absence of active autoimmune disease; c) received live attenuated vaccine within 4 weeks before the first dose of study drug; d) major surgery or severe trauma within 4 weeks before the first dose of study drug;\n6. Human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) active infection or known HIV seropositivity; including HBV or HCV surface antigen positive (RNA)\n7. Uncontrolled cardiac symptoms or diseases, including but not limited to: (1) heart failure above NYHA class II, (2) unstable angina, (3) myocardial infarction within 1 year, (4) clinically significant supraventricular or ventricular arrhythmias without or poorly controlled after clinical intervention;\n8. Severe infection (CTCAE\\>2) occurred within 4 weeks before the first dose of study drug, such as severe pneumonia requiring hospitalization, bacteremia, and infectious complications; Prophylactic antibiotics were excluded if there was active pulmonary inflammation on chest imaging at baseline, if there were signs and symptoms of infection within 14 days before the first dose of the study drug, or if treatment with oral or intravenous antibiotics was required\n9. Participation in other drug clinical studies within 4 weeks before randomization;\n10. Patients with interstitial pneumonia or interstitial lung disease, or previous history of interstitial pneumonia or interstitial lung disease requiring hormone therapy, or other subjects with pulmonary fibrosis, organized pneumonia (such as bronchiolitis obliterans), pneumoconiosis, drug-related pneumonia, idiopathic pneumonia that may interfere with the judgment and treatment of immune related pulmonary toxicity, or subjects with active pneumonia or severe lung function damage revealed by CT during screening; Active pulmonary tuberculosis;\n11. Patients with any active autoimmune disease or history of autoimmune disease and possible recurrence \\[including but not limited to autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism (patients who can be controlled only by hormone replacement therapy can be enrolled)\\]; Patients with skin diseases that do not require systemic treatment, such as leukoplakia, psoriasis, alopecia, patients with type I diabetes that can be controlled by insulin treatment, or patients with a history of asthma, but have completely relieved in childhood and do not need any intervention, can be enrolled; Asthma patients who needed bronchodilators for intervention could not be enrolled; Patients have previously received an anti-PD-1，PD-L1 or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways;\n12. Other malignancies that had been diagnosed within 5 years before the first dose of a study drug were considered unless cancers with a low risk of metastasis or death (5-year survival rate, \\>90%), such as adequately treated basal-cell or squamous-cell skin cancer or carcinoma in situ of the cervix, were considered.\n13. Pregnant or lactating women;\n14. The investigators determined that there were other factors that might have led to the forced discontinuation of the study, such as other serious medical conditions (including mental illness) requiring co-treatment, alcohol, substance abuse, family or social factors, and factors that might have affected the safety or adherence of the subjects.",{"count":420,"type":21},73,[24],"The purpose of this study is to analyze esophageal cancer patients who underwent neoadjuvant immunotherapy with chemotherapy followed by esophagectomy to determine whether additional adjuvant therapy is associated with improved survival outcomes.",[424,263,29],"Esophageal Squamous Cell Carcinoma",[426,427,428,429],"esophageal Squamous Cell Carcinoma","neoadjuvant chemotherapy","neoadjuvant immunotherapy","adjuvant therapy","2023-09-24",{"date":432,"type":38},"2023-09-28",{"date":434,"type":38},"2023-09-07",{"date":436,"type":21},"2026-12-31",{"name":438,"class":45},"Guo Xufeng",{"id":440,"slug":441,"hasResults":11,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":4,"eligibilityCriteria":445,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":446,"targetDuration":4,"studyType":22,"phases":448,"briefSummary":449,"conditions":450,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":462},"100519302","phase-3-adjuvant-befotertinib-in-stage-ib-iiib-non-small-cell-lung-cancer-with-positive-egfr-sensitive-mutations-100519302","NCT06041776","Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations","A Multicenter, Randomized, Controlled, Double Blind, Double Simulated, Phase III Clinical Study of Befotertinib vs Icotinib for Postoperative Adjuvant Treatment of IB-IIIB (T3N2M0) Stage Non Small Cell Lung Cancer With Positive EGFR Sensitive Mutations","Inclusion Criteria:\n\n1. Willingness to sign informed consent prior to any study specific procedures, and ability to with scheduled visits, treatment plans, laboratory tests, and other study procedures.\n2. Male or female, aged at least 18 years.\n3. Histologically confirmed primary NSCLC, and mainly non-squamous cell carcinoma (including mixed type carcinoma mainly composed of adenocarcinoma components).\n4. Absence of brain metastasis.\n5. Complete resection of histologically confirmed Stage IB, II, IIIA or IIIB(T3N2M0) according to the TNM staging system for lung cancer (AJCC\u002FUICC 8th edition), with negative margins.\n6. Confirmation by the central laboratory that the tumor harbors one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R).\n7. Patients who fully recover from surgery during randomization (any surgery must achieve complete postoperative wound healing) and should receive adjuvant treatment within 4-10 weeks after surgery.\n8. ECOG-PS score of 0 or 1 and did not deteriorate 2 weeks before the first administration of the investigational drug, with a minimum expected survival greater than 12 weeks.\n9. Female subjects with fertility need to have a negative serum pregnancy test during screening.\n10. Female subjects who have possibility of becoming pregnant, as well as male subjects whose partners are women of childbearing age, must use a highly effective contraceptive method (such as oral contraceptives, intrauterine devices, abstinence or barrier contraception combined with spermicides) throughout the study and continue to use contraception for 3 months after the end of treatment.\n\nExclusion Criteria:\n\n1. There are unresectable or metastatic diseases, pathological reports showing positive surgical margins under the microscope or extranodal invasion, or lesions left after surgery, or suspicious lesions determined by imaging after surgery. Subjects receiving only wedge resection.\n2. Upper lung groove cancer.\n3. Patient with complete resection of the right lung with NSCLC.\n4. Malignancies other than NSCLC within 5 years prior to first dosage, except for malignant tumors that can be cured after treatment (including but not limited to fully treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or breast ductal carcinoma in situ treated with radical surgery).\n5. Received systematic anti-tumor therapy, including chemotherapy, radiotherapy or targeted therapy (including but not limited to monoclonal antibodies, small molecule tyrosine kinase inhibitors), immunotherapy, investigational therapy, etc., before being enrolled in this study.\n6. Within 3 weeks prior to the first administration of the investigational drug, the patient underwent major surgery (including primary tumor surgery, craniotomy, thoracotomy, or laparotomy, excluding vascular pathway establishment procedures).\n7. Within 14 days prior to first dose of the investigational drug, Traditional Chinese medicine with anti-tumor indications have been received.\n8. After the start of the study, any form of systemic or local anti-tumor treatment (including maintenance therapy with another drug, radiotherapy, and\u002For surgical resection) is still required.\n9. Clinically significant cardiovascular diseases, including:\n\n   1. QTcF interval \\>450 ms (men) or \\>470 ms (women), symptomatic bradycardia (\\\u003C45 beats \u002Fmin), or other significant ECG abnormalities as determined by the investigator (e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, PR interval \\>250 msec).\n   2. Echocardiography showed LVEF \\\u003C50%.\n   3. Hypertension was clinically uncontrollable (e.g., blood pressure \\>160\u002F100 mmHg; Except that isolated elevated readings that were determined by the investigators to be clinically insignificant or controllable hypertension.)\n\n   Within 6 months before the first medication, there were the following situations:\n   1. Congestive heart failure (New York Heart Association rating III or IV).\n   2. Arrhythmias or conduction abnormalities that require medication treatment. Note: Patients with drug-controlled atrial fibrillation\u002Fflutter, as well as those with pacemaker- controlled arrhythmia, can be selected.\n   3. Severe\u002Funstable angina, coronary artery\u002Fperipheral bypass grafting, or myocardial infarction (Note: Severe angina is classified as Grade III or IV by the Canadian Society of Cardiology).\n   4. Cerebrovascular accidents or transient ischemic attacks, transient myocardial ischemia.\n10. Previous history of concomitant interstitial lung disease (ILD), drug-induced ILD, radiation pneumonia requiring hormone therapy, or clinical evidence of concomitant active interstitial lung disease.\n11. Patients who have a history of thrombosis or are currently present with thrombosis or have a potential risk of thrombosis assessed by the investigator.\n12. Any clinical evidence of a serious active infection, or any serious concomitant disease that may affect the subject's acceptance of investigational drugs, such as active bleeding predisposition, active hepatitis B, hepatitis C, or tuberculosis, syphilis, or HIV antibody positive.\n13. There are serious gastrointestinal functional abnormalities in clinical practice that may affect drug intake, transportation, or absorption, such as inability to take medication orally, uncontrollable nausea or vomiting, history of extensive gastrointestinal resection, untreated recurrent diarrhea, atrophic gastritis, untreated stomach diseases requiring long-term use of proton pump inhibitors, gastrointestinal obstruction, active diverticulitis, Crohn's disease, ulcerative colitis, etc.\n14. Abnormal laboratory parameters.\n15. Known hypersensitivity to the befotertinib, icotinib or their inactive excipients.\n16. Within one week before the first administration of the investigational drug, it is currently in use or needs to be combined with CYP3A strong inhibitors or inducers during the study period.\n17. Patients who are still using warfarin within 7 days prior to initial dosing (low molecular weight heparin sodium is allowed).\n18. Participating in clinical research and receiving treatment with the study drug or research device, or participating in clinical research and receiving treatment with the study drug or research device within 4 weeks before the first administration, or planning to participate in any other clinical trial during this study period.\n19. Inoculate with a live vaccine within 180 days before the first medication.\n20. Researchers believe that it may affect protocol compliance or affect the signing of informed consent forms by participants (such as a history of mental illness or drug abuse, alcoholism or other addiction), or any other clinically significant disease or condition that is not suitable for participation in this clinical trial (such as laboratory abnormal results, clinically active diverticulitis, abdominal abscess).",{"count":447,"type":21},570,[210],"This multicenter, randomized, controlled, double-blind, double-simulated, Phase III study is designed to evaluate the efficacy and safety of Befotertinib compared with Icotinib as adjuvant treatment in EGFR-sensitive mutation-positive stage IB-IIIB (T3N2M0) non-small cell lung cancer after surgical resection.",[451,452,29],"Non-Small Cell Lung Cancer","EGFR Sensitive Mutation","2023-09-20",{"date":455,"type":38},"2023-09-22",{"date":457,"type":38},"2023-03-28",{"date":459,"type":21},"2029-11-30",{"name":461,"class":123},"Betta Pharmaceuticals Co., Ltd.",3,{"id":464,"slug":465,"hasResults":11,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":4,"eligibilityCriteria":469,"healthyVolunteers":470,"sex":130,"minAge":17,"maxAge":53,"enrollmentInfo":471,"targetDuration":4,"studyType":22,"phases":473,"briefSummary":474,"conditions":475,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":482,"locationsCount":46},"100461752","phase-2-compare-continuation-of-original-targeted-therapy-with-trastuzumab-combined-with-pyrotinib-and-capecitabine-as-postoperative-adjuvant-therapy-in-non-pcr-patients-with-her2-positive-early-breast-cancer-100461752","NCT05292742","Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer","A Randomized, Open-label, Multicenter Study Comparing Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer","Inclusion Criteria:\n\n* Female patients aged ≥ 18 years and ≤ 75 years old with primary breast cancer\n* ECOG score 0 \\~ 1\n* Breast cancer meets the following criteria: 1）Histologically or pathologically confirmed invasive breast cancer, primary tumor stage determined by standard evaluation methods：cT1-4\u002FN0-3\u002FM0. 2）Pathologically confirmed HER2-expressing positive breast cancer, defined as \\> 10% immunoreactive cells with immunohistochemical (IHC) score of 3 + or in situ hybridization (ISH) results of HER2 gene amplification. 3)Known hormone receptor status (ER and PgR). 4)Neoadjuvant therapy (including: at least 9 weeks of trastuzumab treatment and at least 9 weeks of taxane chemotherapy)\n* Primary breast cancer lesion or lymph node invasive cancer confirmed by pathology after neoadjuvant therapy (residual invasive breast cancer lesion \\> 2 cm or axillary lymph node positive with macrometastasis assessed by central laboratory)\n* No more than 12 weeks between end of surgery (without post-operative radiotherapy) and randomisation or 6 weeks between end of post-operative radiotherapy and randomisation\n* Required laboratory values including following parameters:\n\nANC: ≥ 1.5 x 109\u002FL Platelet count: ≥ 90 x 109\u002FL Hemoglobin: ≥ 9.0 g\u002FdL Total bilirubin: ≤ 1.5 x upper limit of normal, ULN ALT and AST: ≤ 1.5 x ULN BUN and creatine clearance rate: ≥ 50 mL\u002Fmin LVEF: ≥ 55% QTcF: \\\u003C 470 ms\n\nExclusion Criteria:\n\n* 1\\) Stage IV (metastatic) breast cancer;\n* 2\\) inflammatory breast cancer;\n* 3\\) Previous anti-tumor therapy or radiotherapy for any malignancy, excluding cured cervical carcinoma in situ, basal cell carcinoma or squamous cell carcinoma;\n* 4\\) Receiving anti-tumor therapy in other clinical trials, including bisphosphonate therapy or immunotherapy (except radiotherapy and endocrine therapy during treatment);\n* 5\\) Receiving any anti-tumor therapy within 28 days before enrollment;\n* 6\\) Peripheral neuropathy ≥ Grade 2 as specified by NCI CTCAE;\n* 7\\) Receiving pyrrolidone or other anti-HER2 tyrosine kinase inhibitors;\n* 8\\) Receiving anthracycline therapy with cumulative doses as follows: adriamycin \\> 240 mg\u002Fm2, epirubicin \\> 480 mg\u002Fm2;\n* 9\\) Receiving major surgery unrelated to breast cancer before randomization, or the patient has not fully recovered from surgery",true,{"count":472,"type":21},206,[24],"To evaluate the efficacy of continuation targeted therapy compared with trastuzumab combined with Pyrotinib and capecitabine in postoperative adjuvant therapy of HER-2 positive early breast cancer patients with residual tumor (primary breast tumor\u002Faxillary lymph nodes) who did not achieve pCR after neoadjuvant therapy",[159,29],"2022-03-14",{"date":478,"type":38},"2022-03-23",{"date":480,"type":38},"2021-07-02",{"date":271,"type":21},{"name":483,"class":45},"Fujian Medical University Union Hospital",{"id":485,"slug":486,"hasResults":11,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":4,"eligibilityCriteria":490,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":491,"enrollmentInfo":492,"targetDuration":4,"studyType":22,"phases":494,"briefSummary":495,"conditions":496,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":4},"100453589","phase-2-a-study-comparing-ensatinib-versus-platinum-based-chemotherapy-as-adjuvant-treatment-for-stage-ii-iiia-alk--positive-non-small-cell-lung-cancer-100453589","NCT05186506","A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer","A Phase II, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Surgical resection of histologically confirmed Stage IIA to IIIA NSCLC with negative margins, ,within 10 weeks after the operation\n* Documented ALK-positive disease according to FISH , Ventana IHC ,RT-PCR or NGS\n* Eastern Cooperative Group (ECOG) Performance Status score of 0 or 1\n* At least 3-months life expectancy\n* Adequate organ function\n* Any major surgery should be completed at least 4 weeks before the first study drug treatment. Minor surgery\u002Fprocedures must be completed at least 2 weeks before taking medication.\n* Willingness and ability to comply with the trial and follow-up procedures\n* Written informed consents are required to indicate that the patients are aware of the investigational nature of the study\n\nExclusion Criteria:\n\n* More than 10 weeks before surgery Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ\n* Use of other investigational drug within 4 weeks prior to the first dose of Ensartinib\n* Prior stem cell or organ transplant\n* severe cardiovascular disease\n* Presence of active gastrointestinal (GI) disease or other conditions that will interfere significantly with the absorption, distribution, metabolism, or excretion of Ensartinib\n* Active hepatitis B, hepatitis C virus antibody positive, HIV virus antibody, Treponema pallidum antibody positive\n* History of interstitial lung disease, drug-induced interstitial lung disease, history of radiation pneumonitis requiring steroid therapy, or any clinical signs of active interstitial lung disease\n* Reproductive or pregnant or breastfeeding female with a positive serum pregnancy test 7 days before starting treatment , Male or female patients failure to take effective contraceptive measures or plan to give birth during the entire treatment period and 3 months after treatment ends\n* Patients with a known allergy or delayed hypersensitivity reaction to drugs chemically related to ensartinib or to the active ingredient of ensartinib\n* History of drug allergy, such as a history of allergies to pemetrexed, carboplatin or other platinum compounds, or their preventive medications; History of allergies to paclitaxel components; or uncontrolled asthma\n* Patients who have used the following drugs within 14 days before the first dose or who need to use the following drugs during treatment: drugs that cause QTc prolongation and\u002For torsade de pointes-type ventricular tachycardia; strong inhibitors or strong inducers of CYP3A\n* Patients being treated with warfarin or any other coumarin derivative anticoagulant\n* According to the judgment of the investigator, other severe, acute or chronic medical conditions that may increase the risk associated with participating in the study, or may interfere with the interpretation of the study results\n* Concurrent condition evaluated by investigator that would make it inappropriate for the patient to be enrolled","73 Years",{"count":493,"type":21},152,[24],"This randomized, active-controlled, multicenter, open-label, Phase II study is designed to evaluate the efficacy and safety of ensatinib compared with Platinum-Based Chemotherapy as adjuvant treatment in ALK fusion positive II-IIIA stage non-small cell lung cancer after surgical resection",[497,29,451],"ALK Fusion Protein Expression","2022-01-10",{"date":500,"type":38},"2022-01-11",{"date":502,"type":21},"2022-01-01",{"date":504,"type":21},"2028-12-20",{"name":341,"class":45}]